Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
RESEARCH TOOLSreports
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.77Last Year’s EPS
-3.2Same Quarter Last Year
Moderate Sell
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -19.92%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While the company showcased strong cash management, cost reduction, and growth in Cell Engineering revenue, it faced challenges with declining full-year revenue in Cell Engineering and Biosecurity, as well as uncertainty in government contracts. The successful launch of new tools and services offerings provided a positive outlook, but these were offset by the revenue declines in key segments.Company Guidance
During the call, Ginkgo Bioworks provided detailed guidance and updates on various business metrics. The company ended the fourth quarter of 2024 with $562 million in cash, no bank debt, and managed to exceed its original cost-cutting target for the year. Revenue from the Cell Engineering business reached $35 million in Q4, marking a 29% increase from the same quarter in 2023, primarily due to growth with large biopharma and government customers. Despite a full year revenue of $174 million from Cell Engineering services, excluding a $45 million noncash deferred revenue release, the figure was down 10% year-over-year. The Biosecurity business generated $9 million in Q4 with a gross margin of 17%, and its full year revenue was $53 million, down 51% from 2023. Ginkgo aims to achieve adjusted EBITDA breakeven by the end of 2026, with 2025 revenue guidance set between $160 million and $180 million. The company also highlighted significant operational cost reductions and a decrease in cash burn from $114 million in Q3 to $55 million in Q4 of 2024.Cash and Cost Management Achievements
Ended Q4 2024 with $562 million in cash and no bank debt, significantly exceeding original cost-cutting target for 2024 and reducing cash burn from $114 million in Q3 to $55 million in Q4.
Cell Engineering Revenue Growth
Cell Engineering revenue increased by 29% in Q4 2024 compared to Q4 2023, driven by growth with large biopharma customers and government accounts.
Record Number of Technical Milestones
Achieved a record number of technical milestones in Q4 2024, demonstrating strong delivery capability for customers.
Restructuring and Cost Reduction Success
Achieved $190 million annualized run rate reduction through Q4 compared to Q1 2024, surpassing the $100 million spending cut target for 2024.
New Customer Acquisition and Tools Offering
Added 31 new programs and contracts in Q4 2024, with significant traction in new tools and services offerings, including data points and automation.
---
DNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $10.29 | $9.11 | -11.47% |
| Nov 12, 2024 | $8.39 | $8.60 | +2.50% |
| Aug 08, 2024 | $11.43 | $10.81 | -5.42% |
| May 09, 2024 | $36.80 | $30.44 | -17.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ginkgo Bioworks Holdings (DNA) report earnings?
Ginkgo Bioworks Holdings (DNA) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Ginkgo Bioworks Holdings (DNA) earnings time?
Ginkgo Bioworks Holdings (DNA) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DNA EPS forecast?
DNA EPS forecast for the fiscal quarter 2025 (Q1) is -1.77.
---
